GlassScriptPhysician profile
Leslie Milton Dally
NPI 1306093877
$864.07
in general payments reported to CMS, 2019-2025
9 companies · $387 in 2025
The $387 reported for 2025 was more than what 83% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
See the full distribution for Addiction Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.63 · 2020: $102 · 2021: $36.06 · 2022: $160 · 2023: $49.26 · 2024: $50.50 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.01 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $341.97 | 2019-2025 | Sublocade |
| Braeburn INC. | $172.22 | 2025 | Brixadi |
| Alkermes, INC. | $119.26 | 2020-2025 | Vivitrol |
| Abbvie INC. | $101.26 | 2019-2025 | |
| Gilead Sciences, INC. | $59.20 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $29.45 | 2019 | |
| Hikma Pharmaceuticals USA | $14.00 | 2023 | Kloxxado |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.73 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Dally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.